{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:14:26Z","timestamp":1788243266884,"version":"build-2803163510"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Nail psoriasis (NP) is refractory in children, causing punctate pits, onycholysis, subungual hyperkeratosis and discoloration, impairing quality of life. We report a 14-year-old boy with 4-year NP, all fingernails involved with no cutaneous lesion, and unresponsive to traditional therapy. After 20-week oral upadacitinib, all nail lesions achieved near-complete resolution with only minimal residual nail changes, and no treatment-related adverse events. This suggests that upadacitinib demonstrates favorable efficacy and safety for pediatric refractory NP, large-scale prospective clinical investigation are warranted to validate our findings.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1941127","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:26:38Z","timestamp":1788240398000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Near-complete resolution of nail psoriasis with upadacitinib in a pediatric patient"],"prefix":"10.3389","volume":"17","author":[{"given":"Yulin","family":"Huang","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijian","family":"Wen","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Guangxi Medical University","place":["Nanning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2022.01.006","article-title":"Psoriasis ungueal","volume":"113","author":"Canal-Garc\u00eda","year":"2022","journal-title":"Actas Dermo-Sifiliogr"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.12788\/cutis.0386","article-title":"Management of pediatric nail psoriasis","volume":"108","author":"Plachouri","year":"2021","journal-title":"Cutis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17138","article-title":"Dermoscopic features of nail psoriasis: a systematic review","volume":"63","author":"RaChadi","year":"2024","journal-title":"Int J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000512688","article-title":"The impact of nail psoriasis and treatment on quality of life: a systematic review","volume":"7","author":"Stewart","year":"2021","journal-title":"Skin Appendage Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3109\/1061186X.2014.929138","article-title":"Insights into drug delivery across the nail plate barrier","volume":"22","author":"Saner","year":"2014","journal-title":"J Drug Targeting"},{"key":"B6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40257-023-00786-4","article-title":"Efficacy and safety of nail psoriasis targeted therapies: a systematic review","volume":"24","author":"Hwang","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02053.x","article-title":"Onychomycosis in patients with psoriasis \u2013 a multicentre study","volume":"55","author":"Zisova","year":"2012","journal-title":"Mycoses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2215987","article-title":"Updates in treatment and impact of nail psoriasis","volume":"19","author":"Iorizzo","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.072","article-title":"Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus","volume":"81","author":"Rigopoulos","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/14740338.2023.2227560","article-title":"Safety of current systemic therapies for nail psoriasis","volume":"22","author":"Hwang","year":"2023","journal-title":"Expert Opin Drug Saf"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17049","article-title":"Pediatric psoriasis: understanding pathological conditions and advances in treatment","volume":"51","author":"Morita","year":"2024","journal-title":"J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/12034754251409046","article-title":"Oral JAK and TYK2 inhibitors in the management of nail psoriasis: an evidence-based review","author":"Waked","year":"2025"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X251387391","article-title":"Dramatic clearance of extensive psoriasis in a pediatric patient treated with upadacitinib: a case report","volume":"13","author":"Mistry","year":"2025","journal-title":"SAGE Open Med Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/children11080892","article-title":"Biologics and small molecule targeted therapies for pediatric alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa in the US: a narrative review","volume":"11","author":"Yi","year":"2024","journal-title":"Children"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2246604","article-title":"Upadacitinib in nail psoriasis: a case report","volume":"34","author":"Wang","year":"2023","journal-title":"J Dermatol Treat"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586792","article-title":"Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: A systematic review and meta-analysis","volume":"16","author":"Chai","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4081\/reumatismo.2024.1685","article-title":"Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review","volume":"77","author":"Perricone","year":"2024","journal-title":"Reumatismo"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3441","article-title":"Extrapolation of upadacitinib efficacy in juvenile idiopathic arthritis leveraging pharmacokinetics, exposure\u2013response models, and real\u2010world patient data","volume":"116","author":"Qian","year":"2024","journal-title":"Clin Pharma Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S433367","article-title":"JAK inhibitors in psoriatic disease","volume":"16","author":"Megna","year":"2023","journal-title":"CCID"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1941127\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:26:41Z","timestamp":1788240401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1941127\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":19,"alternative-id":["10.3389\/fimmu.2026.1941127"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1941127","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1941127"}}